The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: protein affinity chromatography. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Protein affinity chromatography is a key innovation area in the pharmaceutical industry
Protein affinity chromatography is a powerful technique used to separate and purify proteins based on their specific interactions with immobilized ligands or molecules. The technique exploits the binding affinity between a target protein and a ligand that is covalently attached to a solid support matrix. Protein affinity chromatography is widely used in biochemical research, biotechnology, and the pharmaceutical industry for the isolation and purification of specific proteins.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of protein affinity chromatography.
Key players in protein affinity chromatography – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to protein affinity chromatography
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche is one of the leading patent filers in protein affinity chromatography. Roche is involved in the development of diagnostic tests and technologies, as well as research and development in the field of biotechnology and drug discovery. While Roche is not primarily a manufacturer of chromatography resins or columns, they utilize protein affinity chromatography in their research and development processes, especially in the purification and characterization of proteins for diagnostic and therapeutic purposes. E. Merck and Sanofi are some of the other key patent filers in protein affinity chromatography.
In terms of application diversity, Nanopareil leads the pack, while Porvair and Genclis stood in second and third positions, respectively. By means of geographic reach, Sanofi held the top position, followed by AbbVie and Johnson & Johnson.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.